{"id":"https://openalex.org/A5154409490","orcid":"https://orcid.org/0009-0003-2987-2531","observed_orcids":["https://orcid.org/0009-0003-2987-2531"],"display_name":"Sudha Murugesan","raw_author_names":["Sudha Murugesan"],"full_name":"Sudha Murugesan","works_count":6,"cited_by_count":0,"summary_stats":{"2yr_mean_citedness":0.0,"h_index":0,"i10_index":0},"ids":{"openalex":"https://openalex.org/A5154409490","orcid":"https://orcid.org/0009-0003-2987-2531","observed_orcids":["https://orcid.org/0009-0003-2987-2531"]},"affiliations":[{"institution":{"id":"https://openalex.org/I85461943","ror":"https://ror.org/0034me914","display_name":"Saveetha University","country_code":"IN","type":"education","lineage":["https://openalex.org/I85461943"]},"years":[2026]}],"last_known_institutions":[{"id":"https://openalex.org/I85461943","ror":"https://ror.org/0034me914","display_name":"Saveetha University","country_code":"IN","type":"education","lineage":["https://openalex.org/I85461943"]}],"topics":[{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","count":2,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","count":1,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","count":1,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","count":1,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","count":1,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"topic_share":[{"id":"https://openalex.org/T13991","display_name":"Nuclear Receptors and Signaling","value":1.7e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","value":1.62e-05,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13796","display_name":"Neuroprotection in Cerebral Ischemia","value":9.6e-06,"subfield":{"id":"https://openalex.org/subfields/2808","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11253","display_name":"Nail Diseases and Treatments","value":7.9e-06,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10704","display_name":"Advancements in Transdermal Drug Delivery","value":7.1e-06,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"x_concepts":[{"id":"185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","score":0.8679999709129333},{"id":"207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","score":0.6345000267028809},{"id":"181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","score":0.40220001339912415},{"id":"193042331","wikidata":"https://www.wikidata.org/wiki/Q1772003","display_name":"Structure\u2013activity relationship","score":0.33079999685287476},{"id":"17077164","wikidata":"https://www.wikidata.org/wiki/Q1185869","display_name":"Inhibitory postsynaptic potential","score":0.28630000352859497}],"counts_by_year":[{"year":2026,"works_count":6,"oa_works_count":6,"cited_by_count":0}],"display_name_alternatives":["Sudha Murugesan"],"block_key":"s murugesan","works_api_url":"https://api.openalex.org/works?filter=author.id:A5154409490","awards_count":0,"awards_api_url":"https://api.openalex.org/awards?filter=investigators.author.id:A5154409490","updated_date":"2026-11-10T14:30:39","created_date":"2026-10-03T00:00:00"}